Table 2. Drug resistance patterns of isolates to first- and second-line anti-TB drugs with TB patient category of study participants in the Tigray Region, northern Ethiopia, July 2018 to August 2019.
| First-line resistance pattern | New cases (n = 172), F (%) | Previously treated cases (n = 55), F (%) | Total cases (n = 227), F (%) | |
|---|---|---|---|---|
| Any-S | 152 (88.4) | 37 (67.3) | 189 (83.3) | |
| RIF-R | 21 (12.2) | 19 (34.5) | 40 (17.6) | |
| RIF mono- R | 1 (0.6) | 1 (1.8) | 2 (0.9) | |
| RIF-S | 151 (87.8) | 36 (65.5) | 187 (82.4) | |
| INH-R | 23 (13.4) | 18 (32.7) | 41 (18.1) | |
| INH mono-R | 3 (1.7) | 0 (0) | 3 (1.3) | |
| INH-S | 149 (86.6) | 37 (67.3) | 186 (81.9) | |
| Any-R | 24 (14) | 19 (34.5) | 43 (18.9) | |
| MDR | 20 (11.6) | 18 (32.7) | 38 (16.7) | |
| Second-line resistance pattern (38) | New cases (20), F (%) | Previously treated cases (18), F (%) | Total cases (38), F (%) | |
| FLQ | R | 0 | 2 (11.1) | 2 (5.3) |
| S | 20 (100) | 16 (88.9) | 36 (94.7) | |
| AMK, CAP, KAN | R | 0 | 0 | 0 |
| S | 20 (100) | 18 (100) | 38 (100) | |
| KAN, CAP, VIO | R | 0 | 0 | 0 |
| S | 20 (100) | 18 (100) | 38 (100) | |
| KAN, AMK, CAP, VIO | R | 0 | 0 | 0 |
| S | 20 (100) | 18 (100) | 38 (100) | |
| Low-level KAN | R | 0 | 0 | 0 |
| S | 20 (100) | 18 (100) | 38 (100) | |
R = resistant, S = susceptible, FLQ = Fluoroquinolones (Ofloxacin, levofloxacin, Moxifloxacin), AMK = Amikacin, KAN = kanamycin, CAP = Capromycin, VIO = Viomycin.